Skin disease linked to gadolinium
The risk that some patients have for developing a debilitating, life-threatening skin disease linked to the administration of gadolinium calls for close scrutiny of kidney function or even a higher threshold of glomular filtration rate.
The risk that some patients have for developing a debilitating, life-threatening skin disease linked to the administration of gadolinium calls for close scrutiny of kidney function or even a higher threshold of glomular filtration rate.
Nearly 400 cases of nephrogenic systemic fibrosis (NSF) have recently been identified worldwide, and most are related to the administration of gadodiamide (Omniscan, GE Healthcare) in patients with moderate to end-stage kidney disease, according to Dr Henrik Thomsen, a radiologist at Copenhagen University Hospital in Denmark.
Patients with a GFR of < 30 mL/min and those on dialysis are at risk, Thomsen said. There also have been reports of patients with a serum creatinine below 2 mg/dL after gadodiamide administration, suggesting that the threshold could be set higher at < 60 mL/min.
GE Healthcare has posted warnings about gadodiamide on its Web site.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
